Seattle startup HDT Bio will develop a nasal spray designed to counteract a wide range of respiratory viruses with a nearly $1.8 million grant from the...
A joint research team from the LKS Faculty of Medicine, The University of Hong Kong (HKUMed) and City University of Hong Kong (CityU) has discovered that...
Scientists have developed a long-acting delivery system for the tuberculosis drug, rifabutin, that could increase compliance to treatment. The team combined...
As the US embarks on a new delivery strategy to stretch out its thinning supply of monkeypox vaccines, the need for treatments could pick up as...
When Kyle Planck first suspected he might have monkeypox in late June, he went to the CDC website and found six photos of different types of...
Regen BioPharma Inc (OTCMKTS: RGBP) is making a powerful reversal rocketing back into penny land on Friday up 46% on $1.6 million in dollar volume. RGBP...
Nearly half of all vaccines go to waste. This is due to the logistical obstacles involved in transporting them to diverse regions of the world. Most...
There are two approved monkeypox vaccines in the US. Both use a related poxvirus called vaccinia to produce an immune response that protects against smallpox...
We hear a lot about drug-resistant bacteria. The same thing can happen with viruses.
Antibody-drug conjugates are coming back to the fore, with talks of multi-billion dollar buyouts and a rapidly growing The post Oncology market dominance:...
Laboratory Corp of America (Labcorp) has announced that it plans to separate its clinical development business into an The post Labcorp unveils plan to...
Seattle-based Icosavax was one of the companies in the rat race to develop Covid-19 vaccine shots better than Pfizer and Moderna. However, when clinical...
Thursday morning, Takeda reported its quarterly sales ending June 30, 2022. The company reported a 2.4% increase in revenue for the quarter from the same...
The news: Single cell analysis startup Ozette Technologies, with deep roots in the Seattle academic and startup community, has raised $26 million. The...
Dupixent’s march towards becoming one of the world’s top-selling medicines continued at a healthy lick in the second The post Dupixent drives Sanofi...
A needle-free vaccine patch could better fight COVID-19 variants, such as Omicron and Delta, than a traditional needle vaccine according to a University...
Not very long ago, contracting HIV was an effective death sentence; today, there are treatments that allow the The post The continued search for a cure...
Long COVID sufferers may have experienced a wider variety of symptoms than previously thought, new research has found.
Birx Admits She Knew COVID-19 Vaccines Were Never "Going To Protect Against Infection" A year ago, President Biden told the world during a...
A new COVID variant, BA.2.75, has been detected in the UK and several other countries. But the data we have at the moment doesn’t suggest there’s...
Researchers at University of California San Diego School of Medicine, with colleagues elsewhere, describe a different way to build a COVID-19 vaccine,...
Long COVID patients are taking desperate measures in the hope of getting better. It’s time to increase our focus on testing potential long COVID treatments...
With the rise of Omicron last year, there have been a few subvariants introduced — especially BA.2 and BA.5 in the US. Now, there’s another one...
GSK’s former head of vaccines R&D – Dr Emmanuel Hanon – is heading up a new biotech called The post Ex-GSK vaccine chief to lead new...
LA JOLLA, CA — Paramyxoviruses have the potential to trigger a devastating pandemic. This family of viruses includes measles, Nipah virus, mumps, Newcastle...
A Japanese health ministry panel on Wednesday delayed emergency approval for an oral treatment against COVID-19 that has been developed by Shionogi &...
The newly created role will be a unique driver of employee engagement.
Bioregnum Opinion Column by John Carroll MIT finance professor Andrew Lo has more insider connections than just about any other academic player you’ll...
Bioregnum Opinion Column by John Carroll MIT professor Andrew Lo has more insider biotech connections than just about any other academic player you’ll...
Pierre A. Morgon, PharmD, LL.M, MBA, managing director at CanSino Biologics Europe, tells us about Convidecia, a single The post CanSinoBIO developed a...